Clinical significance
CBD3063 is a first-in-class, CRMP2-based peptidomimetic, which
selectively regulates Cav2.2 to achieve analgesia.
A biophysical-based computational pipeline may yield additional active
chemotypes responsible for CBD3’s interaction with
Cav2.2.